Scarica l'app Stockscreener
0.9503
0.43%
-0.0041
Precedente Chiudi:
$0.9544
Aprire:
$0.95
Volume 24 ore:
27,044
Relative Volume:
0.13
Capitalizzazione di mercato:
$40.61M
Reddito:
$8.38M
Utile/perdita netta:
$-27.19M
Rapporto P/E:
-0.8718
EPS:
-1.09
Flusso di cassa netto:
$-13.59M
1 W Prestazione:
+10.41%
1M Prestazione:
+7.25%
6M Prestazione:
-18.43%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.939
$0.9631
Intervallo di 1 settimana:
$0.8071
$1.03
Portata 52W:
$0.65
$1.56
Opus Genetics Inc Stock (IRD) Company Profile
Nome
Opus Genetics Inc
Settore
Industria
Telefono
248-681-9815
Indirizzo
8 DAVIS DRIVE, DURHAM
Confronta IRD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
0.9503 | 40.61M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.76 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.37 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.71 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.39 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.24 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-11 | Iniziato | Craig Hallum | Buy |
| 2024-11-13 | Ripresa | H.C. Wainwright | Buy |
Opus Genetics Inc Borsa (IRD) Ultime notizie
Opus Genetics (IRD) Reveals Promising Gene Therapy Trial Results | IRD Stock News - GuruFocus
Opus Genetics Announces Presentation of OPGX-LCA5 Gene - GlobeNewswire
Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline - Yahoo Finance
Opus Genetics shareholders approve key proposals By Investing.com - Investing.com Nigeria
Opus Genetics shareholders approve key proposals - Investing.com Australia
Ocuphire Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 - marketscreener.com
PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath - markets.businessinsider.com
Opus Genetics (NASDAQ:IRD) Research Coverage Started at Craig Hallum - Defense World
Opus Genetics (IRD) Receives Buy Rating with Promising Gene Ther - GuruFocus
Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns - The Manila Times
Drug company founder pulls plug on proxy fight at her former company - Crain's Detroit Business
Craig-Hallum Initiates Coverage of Opus Genetics (IRD) with Buy Recommendation - Nasdaq
Mina Sooch Issues Open Letter To Opus Genetics' Stockholders - marketscreener.com
Night Vision Disturbances Market to Reach New Heights in Growth - openPR.com
Night Vision Disturbances Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ocuphire Pharma, Viatris - The Globe and Mail
Opus Genetics says Mina Sooch Determined To Withdraw Her Slate Of Nominees For Election To Board - MarketScreener
Opus Genetics issues 1-month pediatric gene therapy results - Optometry Times
Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch - simplywall.st
Opus Genetics reports 1-month pediatric results in gene therapy for inherited retinal disease - Ophthalmology Times
Opus Genetics reports early success in pediatric gene therapy trial - Investing.com
Opus Genetics reports early success in pediatric gene therapy trial By Investing.com - Investing.com India
Opus Genetics Announces One-Month Clinical Data from - GlobeNewswire
Breakthrough: New Gene Therapy Restores Vision in 16-Year-Old Patient Clinical Trial - Stock Titan
Rexahn Pharmaceuticals stock hits 52-week low at $0.81 By Investing.com - Investing.com South Africa
Rexahn Pharmaceuticals stock hits 52-week low at $0.81 - Investing.com
Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company's Transformation and Progress - The Manila Times
Opus Genetics Files Definitive Proxy Statement and Sends - GlobeNewswire
Opus Genetics' Future at Stake: Ex-CEO Challenges $21.5M-Backed Gene Therapy Transformation - Stock Titan
Party Time: Brokers Just Made Major Increases To Their Opus Genetics, Inc. (NASDAQ:IRD) Earnings Forecasts - Yahoo Finance
Opus Genetics Terminates Purchase Agreement with Lincoln Park - TipRanks
Opus Genetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Opus Genetics to Participate in Upcoming Investor Conference in April - GlobeNewswire
Exclusive Ophthalmology Gene Therapy Updates: Opus Genetics CEO Takes Center Stage at RBC Conference - Stock Titan
Opus Genetics (NASDAQ:IRD) Receives Buy Rating from HC Wainwright - Defense World
Opus Genetics (NASDAQ:IRD) Price Target Cut to $8.00 by Analysts at Jones Trading - Defense World
Opus Genetics price target lowered to $8 from $9 at JonesResearch - TipRanks
H.C. Wainwright maintains $8 target on Opus Genetics stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $8 target on Opus Genetics stock - Investing.com
Opus Genetics Announces Full Year 2024 Financial Results, Provides Corporate Update - VisionMonday.com
Opus Genetics earnings missed by $1.22, revenue fell short of estimates - Investing.com Canada
Opus Leans Lower on Year-End Figures - Baystreet.ca
Opus Genetics Announces Financial Results for Full Year 2024 - TradingView
Opus Genetics Transformation: $51.8M Cash Position Powers 4 Clinical Readouts in 2025 - Stock Titan
Ousted founder of drug development company tries to take back the reins - Crain's Detroit Business
Critical Contrast: Mersana Therapeutics (NASDAQ:MRSN) & Opus Genetics (NASDAQ:IRD) - Defense World
Pleasing Signs As A Number Of Insiders Buy Opus Genetics Stock - simplywall.st
Several Insiders Invested In Opus Genetics Flagging Positive News - Yahoo Finance
Opus Genetics Inc Azioni (IRD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Opus Genetics Inc Azioni (IRD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| YERXA BENJAMIN R | President |
Nov 21 '24 |
Buy |
0.98 |
10,000 |
9,834 |
342,800 |
| Magrath George | Chief Executive Officer |
Nov 15 '24 |
Buy |
1.01 |
90,294 |
91,215 |
483,244 |
| Magrath George | Chief Executive Officer |
Nov 18 '24 |
Buy |
1.02 |
9,706 |
9,943 |
492,950 |
| Jayagopal Ashwath | Chief Scientific & Dev. Ofc. |
May 22 '24 |
Buy |
1.76 |
3,500 |
6,178 |
78,500 |
| Magrath George | Chief Executive Officer |
May 17 '24 |
Buy |
1.75 |
5,000 |
8,772 |
430,000 |
0.08%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):